Arcus Biosciences J.P. Morgan Healthcare Conference 2026 Oncology and Immunology Portfolio January 14, 2026 Forward-looking Statements/Safe Harbor Forward-Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this presentation that are not historical facts are forward-looking statements, including ...

Financial Performance & Guidance - GeneDx reported preliminary full year 2025 revenue of $427 million, aligning with previous guidance of $425 to $428 million[73] - The company experienced a 54% growth in exome and genome revenue for full year 2025 (58% excluding a 2024 one-time benefit), exceeding previous guidance of 53% to 55%[73] - Exome and genome volume grew by 30.5% in 2025, meeting the minimum guidance of at least 30%[73] - Adjusted gross margin for 2025 was 71%, consistent with the guided range of 70% to 71%[73] - GeneDx anticipates revenue between $540 to $555 million for full year 2026[76] - The company projects a 33% to 35% growth in exome and genome revenue and volume for 2026[76] Market Position & Growth Strategy - GeneDx holds a leading position with 80% of geneticists preferring their services[8] - The company added 30% more tests to Infinity in 2025 than in the prior 24 years combined[13] - Over 30% of pediatric neurologists now order from GeneDx, indicating strong market penetration[39] - The company's dataset includes >2.5M genetic tests, >50% non-European descent, >8M health records, ~1M exomes & genomes, >7M phenotypic datapoints, and >60% have parental data[25] Expansion & Opportunities - GeneDx is expanding into new markets, including prenatal care, with GenomeDx Prenatal[35, 47] - The company sees a large unmet need in NICUs, where up to 60% of patients could benefit from rWGS, but less than 5% receive genetic testing today[44]

Financial Performance & Growth - Preliminary 2025 total revenue is expected to be approximately $100 million, representing a 25% year-over-year increase[12, 15, 18] - Core RNS System revenue grew by 25% in 2025, driven by sustained demand and increased utilization[12, 18] - Q4 2025 total revenue is estimated at $26.6 million, a 24% increase year-over-year[15] - Gross margin for 2025 is approximately 77.2%, an increase of 330 basis points year-over-year[15] - The company projects revenue between $98 million and $100 million for FY26, with RNS revenue growth of approximately 20-22% and gross margin around 81-82%[21] RNS System & Clinical Data - The RNS System has been used in over 8,000 patients[12] - The RNS System demonstrated a median seizure reduction of 75% at 9 years in the original FDA study results[35] - The RNS Post-Approval Study showed an 82% median seizure reduction at 3+ years[35, 37] - Preliminary NAUTILUS results showed an 18-month median seizure reduction of 77% in LGS patients[61] Market & Expansion - The annual target market opportunity is estimated at over $3.5 billion[12] - Approximately 1.2 million people in the U S have drug-resistant epilepsy (DRE)[25, 56] - The company is focused on expanding access to the RNS System in generalized epilepsy, pediatrics, and community channels[74]

Compass Diversified (NYSE:CODI) Q3 2025 Earnings call January 14, 2026 05:00 PM ET Speaker0At this time, I would like to turn the call over to Ben Tapper, Vice President, Investor Relations. Ben, please go ahead.Speaker2Thank you, and welcome to Compass Diversified's third quarter 2025 conference call. Representing the company today are Elias Sabo, Cody's Chief Executive Officer, and Stephen Keller, Cody's Chief Financial Officer. We are also joined by Zach Sawtelle, Chief Operating Officer for Compass Grou ...

Financial Data and Key Metrics Changes - Net sales grew 23% year over year to $22.7 million in Q4 2025, with full-year revenue increasing 24% to $80.6 million compared to fiscal 2024 [4][5][19] - Gross profit margin for Q4 was 37%, exceeding the 30% target, and for the full year, it was 33%, up from 29% in the prior year [4][5][18][19] - Adjusted EBITDA for Q4 was $2.6 million, compared to $908,000 in Q4 2024, and for the full year, it was $6.1 million, a significant increase from $838,000 in fiscal 2024 [18][19][21] Business Line Data and Key Metrics Changes - The company has shifted from being a product seller to a technology solutions provider, which has diversified its customer base and end markets [6][7] - Key initiatives include deepening relationships with existing customers, leveraging successes in established markets to penetrate new ones, and expanding value propositions for channel partners [8][10] Market Data and Key Metrics Changes - Demand in targeted end markets, including aerospace, stadiums, and transportation, remains strong, with over 130 projects supported in these categories [14][15] - The aerospace and defense market continues to perform well, driven by collaboration with customers to meet stringent requirements [15] Company Strategy and Development Direction - The company aims to diversify end markets, drive customer penetration, and launch new products to sustain strong sales growth and profitability in fiscal 2026 [6][11] - The focus is on operational excellence and innovation aligned with market demand, with a disciplined approach to resource allocation [16][17] Management's Comments on Operating Environment and Future Outlook - Management acknowledges uncertainties in the overall environment but remains confident in executing the long-term strategic plan [6][12] - The expectation for fiscal 2026 is another year of growth, with a similar trajectory to fiscal 2025, despite anticipated seasonality in Q1 [28][29] Other Important Information - The company reduced net debt by $4.6 million compared to last year, with a current ratio of approximately 1.7 to 1 [21][22] - Inventory levels were managed down to $13.7 million from $14.7 million last year, reflecting operational excellence [22][23] Q&A Session Summary Question: Growth trajectory for fiscal 2026 - Management expects another year of growth, with Q1 likely being the lowest quarter of the year due to seasonality [28][29] Question: Breakdown of gross margin expansion - The gross margin increase is attributed to a combination of product mix and higher sales volume, with significant cash flow impact as sales exceed $20 million [31][32] Question: Cost increases and mitigation strategies - Cost increases are nominal and include labor and benefits, with some mitigation possible through pricing and improved sales numbers [38][39] Question: Revenue contribution from diversified markets - Approximately 50% of sales now come from telecom and wireless, with the remaining from transportation, aerospace, and other sectors [53][54] Question: Backlog and bookings analysis - Backlog is expected to hit a low point in Q1 and then increase as project-based work resumes, with Q4 bookings aligning with expectations [55][56][59]

OPKO Health Conference Call Summary Company Overview - **Company**: OPKO Health - **Key Participants**: - Elias Zerhouni - President - Adam Logal - CFO - **Industry**: Biotechnology and Clinical Diagnostics Core Business Components - OPKO Health operates a diverse range of businesses, including: - Clinical diagnostics through BioReference Health - Biotech operations via ModeX Therapeutics, focusing on therapeutics and divesting from clinical diagnostics to improve profitability [6][15] Financial Performance and Strategy - OPKO has divested approximately 40% of its clinical diagnostic business to enhance profitability, focusing on operations in New York and New Jersey [6][15] - The company is nearing break-even and profitability with its remaining clinical diagnostic business, particularly with the 4Kscore cancer diagnostic test, which has shown over 15% growth in testing [7][17] - Guidance for 2026 indicates a projected revenue growth of 3%-5% from a base of approximately $300 million, with a focus on operating efficiency rather than deep investment in commercial operations [18] Key Products and Developments - **4Kscore Test**: - Aids in identifying patients at high risk for aggressive prostate cancer, with a market potential of $25-$30 million [20][21] - Recently received FDA clearance to remove the requirement for a digital rectal exam, potentially increasing adoption [21] - **ModeX Therapeutics**: - Licensed an Epstein-Barr Virus (EBV) vaccine to Merck for $50 million upfront and potential milestones of $870 million [9][10] - The vaccine is in phase one trials, with significant potential for treating cancer and multiple sclerosis [10][25] - **Pipeline Products**: - MDX-2001: A cancer solid tumor product nearing phase 1B trials, targeting multiple cancer types [11][32] - MDX-2004: A trispecific antibody aimed at rejuvenating the immune system, currently in clinical trials [12][42] - Collaboration with Regeneron to develop multiple programs in obesity, metabolism, and cancer [13][52] Milestones and Future Outlook - The company anticipates significant milestones tied to the progression of its vaccine and therapeutic candidates, with potential financial milestones upon entering phase two trials [27][31] - The partnership with Regeneron is expected to yield candidates by the end of the year or early next year, with a focus on combination therapies [53][54] Risk Management and Clinical Trials - OPKO is managing risks associated with clinical trials, particularly concerning cytokine release syndrome (CRS) through established protocols and dose management strategies [36][39] - The company is focused on ensuring safety and efficacy in its trials, with ongoing assessments to determine the most responsive cancer types for its therapies [32][35] Conclusion - OPKO Health is strategically repositioning itself towards a more therapeutics-focused model while maintaining a profitable clinical diagnostics segment. The company is poised for growth with a rich pipeline of products and strategic partnerships that could lead to significant advancements in the biotech space over the next few years [15][30]

RF Industries (NasdaqGM:RFIL) Q4 2025 Earnings call January 14, 2026 04:30 PM ET Company ParticipantsPeter Yin - CFODonni Case - Head of Investor RelationsHoward Root - Retired CEO and Co-FounderRay Bibisi - President and COORob Dawson - CEOConference Call ParticipantsSteve Kohl - AnalystMatthew Maus - Equity Research AnalystOperatorPlease note, this conference is being recorded. I will now turn the conference over to your host, Donnie Case, Investor Relations. You may begin.Donni CaseThank you, John, and g ...

Financial Data and Key Metrics Changes - Revenue for Q1 2026 was $8.3 million, a decrease of 7% compared to $9.3 million in Q1 2025 [13] - Gross operating profit margins were negative 12.5% in Q1 2026, down from positive 18.3% in Q1 2025, primarily due to $2.2 million in additional inventory write-downs [15] - Net loss for Q1 2026 was $3.9 million or negative $1.12 per share, compared to a net loss of $658,000 or negative $0.19 per share in Q1 2025 [17] Business Line Data and Key Metrics Changes - Sales in the core metal fence business increased slightly year-over-year despite challenges, indicating resilience [14] - The Greenwood industrial wood business saw a 45% increase in sales, driven by demand from municipalities and new customers [14] - Decreased sales were noted in lumber and PET products due to market conditions and customer program changes [15] Market Data and Key Metrics Changes - The company faced ongoing challenges from tariffs and negative consumer sentiment, impacting purchasing behavior [11] - The operational environment remains uncertain, with weak consumer sentiment affecting discretionary spending [11] Company Strategy and Development Direction - The company aims to exit fiscal 2026 with a sustainable business model focused on core product categories and operational efficiency [12] - There is a strong emphasis on the metal fencing business as a competitive advantage and a primary focus for capital allocation and innovation [7] - Initiatives to streamline operations and reduce costs are ongoing, with a target to reduce annual operating expenses by $1 million to $3 million [9] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges faced in Q1 but expresses optimism about long-term growth potential, particularly in the metal fencing business [4][7] - The company is making progress in pricing alignment with customers to improve margins, despite the difficulties posed by tariff volatility [16] - Future strategies include monetizing non-core assets and exploring partnerships to strengthen liquidity [10][21] Other Important Information - The company has amended its lending agreement to increase borrowing capacity, providing additional flexibility for operational realignment [19] - Inventory balance decreased to $13.5 million from $15.9 million, with an increased allowance for inventory reflecting market value adjustments [18] Q&A Session Summary Question: Can you expand upon the renegotiated pricing agreements you've entered into? - Management reported successful negotiations for price increases to minimize margin erosion due to tariffs, with implementation beginning in Q1 of fiscal 2026 [24] Question: Can you provide a general breakdown of your inventory by product category? - Management indicated that metal fencing remains the highest velocity inventory, while some PET inventory is slow-moving, with efforts ongoing to move excess lumber inventory [25]

Oculis (NasdaqGM:OCS) FY Conference January 14, 2026 04:30 PM ET Company ParticipantsRiad Sherif - CEOConference Call ParticipantsTessa Romero - Senior Biotech AnalystTessa RomeroWelcome, welcome everyone to the 44th Annual J.P. Morgan Healthcare Conference. My name is Tessa Romero, and I'm one of the senior biotech analysts here at J.P. Morgan. Our next presenting company is Oculis, and presenting on behalf of the company, we have CEO Riad Sherif. Riad, over to you.Riad SherifThank you. Thank you, Tessa. V ...

Zealand Pharma (OTCPK:ZLDP.Y) FY Conference January 14, 2026 04:30 PM ET Company ParticipantsAdam Steensberg - CEOConference Call ParticipantsNone - AnalystNoneGood afternoon and welcome to the Zealand session of the 44th J.P. Morgan Healthcare Conference. My name is Safiya Graff. I'm an analyst here at J.P. Morgan on the European Pharma and Biotech team. And today it's my pleasure to welcome Adam Steensberg, CEO of Zealand Pharma, to the conference. As a reminder, after the presentation, there will be a Q& ...